During the last decade there have been revolutionary breakthroughs in understanding the biology of pheochromocytomas and extra-adrenal paragangliomas. Discoveries of new susceptibility genes and genotype-phenotype correlations have led to the realization that appropriate patient care requires a complete integration of clinical, genetic, biochemical, imaging, and pathology findings. Clinical practice has in many cases not kept pace with the rate of discovery, underscoring a need for updated procedures for evaluation of patient specimens and reporting of data. We therefore propose a new synoptic reporting approach for pheochromocytomas and extra-adrenal paragangliomas that will provide clear and uniform information to pathologists and clinicians, in order to advance the diagnosis of these neoplasms and optimize patient care.
INTRODUCTION
During the last decade there have been revolutionary breakthroughs in understanding the biology of pheochromocytomas and extra-adrenal paragangliomas. It is now recognized that at least 30% of these tumors are hereditary, caused by germline mutations of at least 10 genes [1] [2] [3] [4] [5] [6] [7] [8] [9] . Hereditary pheochromocytomas and extra-adrenal paragangliomas arising in patients with different genotypes have characteristic distributions and biochemical profiles and different likelihoods of metastasis [6] [7] [8] [9] . In addition, a widening spectrum of associated tumors -including gastrointestinal stromal tumors, renal cell carcinomas, and pituitary adenomas -is associated with newly discovered hereditary tumor syndromes. Discoveries of new susceptibility genes and genotype-phenotype correlations have led to the realization that appropriate patient care requires a complete integration of clinical, genetic, biochemical, imaging, and pathology findings [6] [7] [8] [9] . There is a corresponding need for updates in clinical practice to incorporate these recent discoveries. We therefore propose a new synoptic reporting approach for pheochromocytomas and extra-adrenal paragangliomas that will provide clear and uniform information to pathologists and clinicians, in order to advance the diagnosis of these neoplasms and optimize patient care.
SCOPE OF GUIDELINES
Beyond differential diagnosis, pathologists play important roles in identifying clues to hereditary disease and alerting clinicians to possible associated lesions and their significance. The proposed checklist aims to provide uniform and complete data to allow thorough evaluation of pheochromocytomas and extra-adrenal paragangliomas. This checklist will guide pathologists to issue standardized reports. It does not include the detailed information required to reach the diagnosis of pheochromocytoma or extra-adrenal paraganglioma; that is provided elsewhere [1] [2] [3] [4] [5] . A novel component of the checklist is a formatted clinicopathologic correlation. 
PATHOLOGY CASE SUMMARY (CHECKLIST)
Select
EXPLANATORY NOTES
A: Anatomical Sites of Paraganglia-Paraganglia are neural crest-derived neuroendocrine organs that produce predominantly catecholamines [1] [2] [3] . Paraganglia are typically divided into two groups based on parasympathetic or sympathetic nervous system origin. Sympathetic paraganglia are also divided into two subgroups: the adrenal medulla, so-called "sympathoadrenal paraganglia" and extra-adrenal sympathetic paraganglia [3] [4] [5] . The anatomic site impacts the nomenclature of tumors arising from paraganglia; while tumors arising from the adrenal medulla are termed "pheochromocytomas", tumors arising from extra-adrenal locations are called "paragangliomas" regardless of their sympathetic or parasympathetic origins [1] [2] [3] [4] [5] . Furthermore, the anatomic site of a tumor predicts the risk of malignancy, since extra-adrenal paragangliomas exhibit a higher risk of malignancy [1] [2] [3] [4] [5] [6] [7] [8] .
B: Clinical and Biochemical Features-While pheochromocytomas and the majority of sympathetic paragangliomas are often associated with clinical symptoms, only a small percentage of parasympathetic paragangliomas are symptomatic 1 . Many clinically silent paragangliomas, particularly of the sympathoadrenal type will produce metanephrines and/ or methoxytyramine and therefore be amenable to biochemical testing 7, 9 . However, parasympathetic paragangliomas often lack tyrosine hydroxylase, the enzyme required for catecholamine synthesis, and are therefore usually non-functional 2 .
Similar to other neuroendocrine neoplasms, pheochromocytomas and extra-adrenal paragangliomas are also capable of producing and secreting other peptides that can cause clinical syndromes. Production of ACTH (adrenocorticotropic hormone), β-endorphin, CRH (corticotropin-releasing hormone), calcitonin gene-related peptide, VIP (vasoactive intestinal peptide), GHRH (growth hormone-releasing hormone), neuropeptide Y, peptide YY, IGF-1 (insulin like growth factor-1), galanin, adrenomedullin, serotonin, somatostatin and gastrin-like neuropeptide have been reported [1] [2] [3] [4] [5] [10] [11] [12] [13] [14] [15] [16] [17] .
Recent molecular data suggest genotype-phenotype correlations in paragangliomas with respect to tumor distribution, catecholamine production and risk of metastasis 2, 7, [18] [19] [20] [21] [22] [23] . It is now recognized that at least 30% of paragangliomas and pheochromocytomasare associated with familial syndromes 2, 3, 18 . Specific genotype-biochemical correlations highlight the importance of laboratory testing to characterize patterns of catecholamine excess. Since catecholamines (dopamine, norepinephrine, and epinephrine) are not continuously secreted in normal conditions, biochemical testing for the O-methylated metabolites of dopamine, norepinephrine and epinephrine (methoxytyramine, normetanephrine and metanephrine, respectively) in plasma and/or urine is superior to measurement of the parent catecholamines 7, 22, 23 . In terms of their biochemical profile, SDHx (Succinate dehydrogenase, x refers to all subunits, e.g. SDHA refers to subunit A)-related tumors are associated with dopamine and/or norepinephrine production, VHL (Von Hippel-Lindau)-related tumors are associated with norepinephrine production, RET (Rearranged during transfection)-and NF-1 (Neurofibromin 1)-related tumors are associated with epinephrine production 2, 7 . Moreover, the risk of malignancy is significantly higher in SDHB (Succinate dehydrogenase subunit B)-related chromaffin cell tumors, which are usually observed in extra-adrenal locations and reach larger sizes with much lower tissue concentrations of catecholamines than other paragangliomas 7, [19] [20] [21] [22] [23] . These data are of clinical significance in that integration of the biochemical profile with other information, such as tumor location and dimensions, becomes an important part of comprehensive synoptic reporting.
C: Functional Imaging: Tumor Scintigraphy or Positron Emission
Tomography (PET)-Similar to the genotype-biochemical profile correlations of paragangliomas, the functional status of a paraganglioma has an impact on imaging modalities that are used to localize these lesions 18 . 123 I-metaiodobenzylguanidine scintigraphy (123I-MIBG) and 18 F-6-fluorodopamine (18F-FDA) or 18 F-6-fluorodihydroxphenylalanine (18F-FDOPA) PET, are superior to other functional imaging modalities for detecting pheochromocytomas 18, 24 . In contrast, 18 F-fluorodeoxyglucose (18-F-FDG) PET is more useful than other modalities for diagnostic localization of SDHBdriven metastatic paragangliomas 18, 24 , whereas 18F-DOPA PET has been reported to be the most effective functional imaging modality for localization of SDHx-related head and neck paragangliomas 25 . Recently, it has been shown that 18F-FDOPA PET is most useful for the detection of head and neck paragangliomas and neuroendocrine neoplasms arising in patients with VHL syndrome 26, 27 . When available, the integration of functional imaging data is of clinical interest and will ascertain the completeness of the synoptic report.
D: Tumor Location, Size, Weight and Focality-The significance of tumor location with respect to the parasympathetic/sympathetic origin of the tumor, and correlation with the biochemical profile and the appropriate terminologies are discussed in detail in parts A and B. Therefore, the anatomic location of the tumor must be clearly specified in the synoptic report with the appropriate classification based on location.
Similar to other guidelines, tumor size is a required field in surgical pathology reports. Numerous reports have indicated that malignant tumors are heavier and larger than tumors with benign behavior 3, 6, 23, [28] [29] [30] [31] . Although the tumor size and weight are not universally considered independent parameters, a cut-off of 5-6 cm diameter and 80-150 gram weight have been suggested to predict malignant behavior 23, [28] [29] [30] [31] .
The issue of multifocality is of interest and should be included in the synoptic report [1] [2] [3] [4] [5] .
Patients with multiple paragangliomas should be investigated for the possibility of underlying genetic susceptibility and thus genetic testing for RET, NF-1, VHL, SHDx, TMEM127 (Transmembrane protein 127), MAX (MYC associated factor-X) and KIF1Bβ (Kinesin family member 1B) mutations should be considered 1, 3, 19, 20, [32] [33] [34] [35] [36] . While the value of systematic genetic screening for "sporadic" cases remains controversial, clinical features including family history, along with the biochemical and morphological features (multifocality, adrenal medullary hyperplasia, thick capsule, clear cell morphology), and immunoprofile (loss of SDHB and SDHA expression) 36, 37 (see parts B, F, I and J) can provide important insight to determine which gene(s) should be screened preferentially in patients with pheochromocytomasand/or extra-adrenal paragangliomas. Multifocality includes multiple pheochromocytomas in the same adrenal.
E: Classification-Anatomic location impacts the terminology used for these tumors. In the presence of metastatic disease, the term "metastatic" should be used. The term "composite" is used when a tumor combines features of paraganglioma or pheochromocytoma with those of malignant peripheral nerve sheath tumor, ganglioneuroma, ganglioneuroblastoma and neuroblastoma. Comprehensive data related to neuroblastic and related components should be reported using the designated synoptic checklist 38 . The histological classification generated from the recommendations of the 2004 World Health Organization Classification of Tumors of Endocrine Organs 1 is listed below, however for simplicity; the format proposed is shortened to allow a practical approach for synoptic reporting. Genotype-phenotype correlations highlighted that VHL-related tumors contain usually a thick vascular capsule, hyalinized and myxoid stroma, round tumor cells intermingled with small vessels, cells with predominantly amphophilic and clear cell cytoplasm, absence of intracytoplasmic hyaline globules, lipid degeneration 39 and lack of nuclear atypia or mitoses 1, 3 .
Classification of Pheochromocytomas and
The term "composite" should be used when a tumor combines features of paraganglioma or pheochromocytoma with those of malignant peripheral nerve sheath tumor, ganglioneuroma, ganglioneuroblastoma and neuroblastoma. Comprehensive data related to neuroblastic and related component should be reported by using the designated synoptic checklist 38 . In this setting, corticomedullary tumors, cauda equina Paragangliomasshowing ependymal differentiation as well as gangliocytic paragangliomas that include Schwann-like cells and ganglion cells do not qualify as composite tumors 1, 4 . Moreover, scattered mature ganglion cells seen in pheochromocytomas/paragangliomas should not be misinterpreted as a component of a composite tumor [1] [2] [3] [4] .
No single histological parameter is able to predict malignant behavior in paragangliomas and pheochromocytomas [1] [2] [3] [4] [5] . Tumor necrosis is uncommon in these tumors and degenerative changes should not be mistaken as necrosis [1] [2] [3] [4] [5] . However, expanded large confluent nests with central comedo necrosis, which are at least three times greater than conventional small nests, have been described in some malignant pheochromocytomas/paragangliomas [1] [2] [3] [4] . Therefore, a distinction should be made between focal (small microscopic foci or single cell necrosis) and extensive (central, expansive or "comedo" necrosis). Increased mitoses (>3/10 High Power Fields, HPF) and atypical mitotic figures have been reported in some malignant cases 1, 3, 4 , but mitoses are usually very rare even in malignant cases. There is currently no standard approach to mitotic count in pheochromocytoma/paraganglioma. On the basis of established methodology for other neuroendocrine tumors, it has been recommended that mitotic count should be based upon counting 50 HPF (40x objective) and in the area of highest mitotic activity, and reported as number of mitoses per 10 HPF. However, taking into consideration the variations in field size, providing the number of mitosis per mm 2 seems to be more appropriate. The College of American Pathologist Breast Cancer Protocol 40 recommends that the size of HPF be measured by using a micrometer. Alternatively, it has been suggested that that the high power field diameter/area can also be calculated by using the following formulas 40 [1] [2] [3] . Moreover, unlike other neoplasms, vascular invasion is also not universally accepted as an unequivocal predictor of malignant potential in paragangliomas and pheochromocytomas [1] [2] [3] . However, it is important to document the invasiveness of these tumors. Moreover, strict criteria to diagnose vascular invasion (intravascular tumor cells associated with thrombus) and capsular invasion (transcapsular) should be applied as they are in other endocrine organs 41 . As discussed in part F, the presence of a thick vascular capsule may raise the suspicion of a VHL-related paraganglioma [1] [2] [3] .
H: Metastases-An extra-adrenal location, large size, and the presence of SDHB mutations are all important risk factors for metastatic spread 6, 7, 21, 23, 42 . High rates of malignancy in tumors associated with SDHB mutations can be fully accounted by both their typically extra-adrenal location and large size 23 . While tumors arising from head and neck paragangliomas are much less often metastatic, mediastinal and intraabdominal paragangliomas appear to often be associated with metastatic disease 1, 3, 6, 8 .
The diagnosis of metastasis is appropriate when dealing with a site where no paraganglial tissue is observed; it is crucial to remember the normal anatomic distribution of paraganglia as discussed in part A, to consider the possibility of multifocal primaries. The pathology report should state the total number of lymph nodes examined, the number of nodes with metastases, and nodal involvement should be reported as macrometastasis (>2mm) or micrometastasis (≤2mm and including isolated tumor cells) based on the size of the metastatic deposit. While the determination of the nodal disease is easy, the assessment of distant metastasis can be challenging in the setting of multifocal disease, since primary paragangliomasdo also occur in rare anatomical sites such as thyroid, pituitary, gallbladder, and lung 2, 4, [43] [44] [45] . Therefore, these rare locations should not be considered metastatic ab initio.
I: Immunohistochemistry-Positivity for tyrosine hydroxylase, which is the rate limiting enzyme in the synthesis of catecholamines 46 , is very helpful to distinguish paragangliomas from other neuroendocrine carcinomas, which can also be negative for cytokeratins 2 . However, positivity for chromogranin-A and tyrosine hydroxylase is usually weaker and more variable in parasympathetic paragangliomas than in sympathetic paragangliomas and is sometimes negative 2 . Some of these tumors selectively express chromogranin B. S100 protein is typically used to highlight the sustentacular network in paragangliomas; however, the reactivity pattern is usually variable. It is of note that epithelioid endocrine cells and spindled Schwann-like cells of gangliocytic paragangliomas can be positive for cytokeratin and S100 protein, respectively 1, 4 . Moreover, cauda equina paragangliomas, which are usually intradural lesions limited to the filum terminale, may show ependymal and neuronal differentiation and can be positive for cytokeratin 1, 4, 47 .
There is currently no standard approach to scoring Ki-67 in pheochromocytomaand paraganglioma. On the basis of established methodology for other neuroendocrine tumors, it is recommended that Ki-67 index should be reported as percentage of positive tumor cells in area of highest nuclear labeling 48 .
Loss of SDHB expression is regarded as a surrogate marker for some of the familial paraganglioma syndromes caused by SDHx mutations 36 , therefore immunohistochemical testing for SDHB has become a part of the routine assessment of these lesions in many centers. Moreover, the use of SDHB antibody not only allows the identification of SDHx related tumors, but also provides prognostic data, due to the high rate of malignancy associated with SDHB-driven paragangliomas 7, 21, 24, 42 . Recently, it was also demonstrated that SDHA immunohistochemistry is also very useful to reveal the presence of SDHA germline mutations 37 ; PGLs associated with germline SDHA mutation show negative staining for SDHA as well as SDHB.
J: Associated Lesions-It is widely accepted that adrenal medullary hyperplasia is a precursor lesion of pheochromocytomas arising in MEN 2 (Multiple endocrine neoplasia type 2) syndromes and is characterized by a nodular and/or diffuse enlargement of the adrenal medulla [1] [2] [3] [4] [5] . Although other predisposing genetic syndromes are not usually associated with adrenal medullary hyperplasia, it is noteworthy that a 61-year-old man with an SDHB mutation was found to have bilateral adrenal medullary hyperplasia characterized by an increased cortex to medulla ratio of 1:1 in both glands 49 . Other exceptions might also exist.
The determination of underlying adrenal medullary hyperplasia is one of the clinical responsibilities of pathologists examining adrenal glands. When examining diffuse hyperplasia, it is important to remember that medulla is normally present only in the head and body, but not in the tail of the gland with only minimal extension into the alae [3] [4] [5] .
Although it is sometimes hard to define the tail of the adrenal due to distortion of the gland by tumor, the presence of adrenal medullary tissue in the tail qualifies as adrenal medullary hyperplasia [3] [4] [5] . In general, medulla should not represent more than one-third of the gland thickness, with cortex on each side comprising the other two thirds. The distinction of pheochromocytoma from nodular adrenal medullary hyperplasia is arbitrary since even microscopic nodules observed in the setting of MEN 2 syndrome represent clonal proliferations; therefore they are indeed neoplastic lesions 3, 5 . However, nodules less than 1 cm can be practically considered to represent hyperplasia 4 , provided that they grossly and microscopically resemble the rest of the medulla. It should be remembered that adrenal medullary nodules and pheochromocytomas can occur in MEN 2 adrenals without an obvious background of diffuse hyperplasia. The adrenal adjacent to an apparently sporadic pheochromocytoma should therefore be "breadloafed" and carefully examined for small nodules.
